ClinicalTrials.Veeva

Menu

Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

P

Pursuit Vascular

Status

Completed

Conditions

End Stage Renal Disease (ESRD)

Treatments

Device: ClearGuard HD end cap

Study type

Interventional

Funder types

Industry

Identifiers

NCT02604264
CLP-0001

Details and patient eligibility

About

To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.

Enrollment

2,912 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients dialyzing with a central venous catheter

Exclusion criteria

  • Known allergy to chlorhexidine

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

2,912 participants in 2 patient groups

ClearGuard HD end cap
Active Comparator group
Description:
Treatment
Treatment:
Device: ClearGuard HD end cap
Standard hemodialysis end cap
No Intervention group
Description:
Control

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems